Compound class:
Synthetic organic
Comment: Compound 19a is the most potent of a series of STAT6 inhibitors reported by Mandal et al. (2015) [1]. STAT6 inhibitors are being developed for their potential to inhibit the expression of genes contributing to asthma. Compound 19a is a phosphopeptide mimic that blocks interaction of the IL-4 and IL-13 receptors with the SH2 domain of STAT6, thereby preventing the downstream transcriptional sequelae of STAT6 activation. The structure is claimed in patent WO2014182928 [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Mandal PK, Morlacchi P, Knight JM, Link TM, Lee 4th GR, Nurieva R, Singh D, Dhanik A, Kavraki L, Corry DB et al.. (2015)
Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity. J Med Chem, 58 (22): 8970-84. [PMID:26506089] |
2. McMurray JS, Mandal PK, Morlacchi P, Knight M, Corry DB. (2014)
Stat6 inhibitors. Patent number: WO2014182928. Assignee: Board Of Regents, The University Of Texas System, Baylor College Of Medicine. Priority date: 08/05/2013. Publication date: 13/11/2014. |